Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)

Compounds that inhibit HYDROXYMETHYLGLUTARYL COA REDUCTASES. They have been shown to directly lower CHOLESTEROL synthesis.

Also Known As:

HMG-CoA Reductase Inhibitors; Inhibitors, HMG-CoA Reductase; Inhibitors, Hydroxymethylglutaryl-CoA; Inhibitors, Hydroxymethylglutaryl-Coenzyme A; Statins; HMG CoA Reductase Inhibitor; HMG CoA Reductase Inhibitors; HMG-CoA Statins; Hydroxymethylglutaryl CoA Reductase Inhibitor; Hydroxymethylglutaryl CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA Inhibitors; Hydroxymethylglutaryl-Coenzyme A Inhibitors; Inhibitors, HMG CoA Reductase; Inhibitors, Hydroxymethylglutaryl CoA; Inhibitors, Hydroxymethylglutaryl Coenzyme A; Inhibitors, Hydroxymethylglutaryl-CoA Reductase; Reductase Inhibitor, Hydroxymethylglutaryl-CoA; Reductase Inhibitors, HMG-CoA; Reductase Inhibitors, Hydroxymethylglutaryl-CoA; Statins, HMG CoA; HMG-CoA Reductase Inhibitor; Hydroxymethylglutaryl-CoA Reductase Inhibitor; Statin; Statins, HMG-CoA

Networked: 26301 relevant articles (2674 outcomes, 6656 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Therapeutic Uses: 47080
    - Lipid Regulating Agents: 18
      - Hypolipidemic Agents: 776
        Anticholesteremic Agents: 22
        Hydroxymethylglutaryl-CoA Reductase Inhibitors: 26301
  - Molecular Mechanisms of Pharmacological Action: 24
    - Enzyme Inhibitors: 1659
      - Hydroxymethylglutaryl-CoA Reductase Inhibitors: 26301
    - Antimetabolites: 1599
      - Hypolipidemic Agents: 776
        Anticholesteremic Agents: 22
        Hydroxymethylglutaryl-CoA Reductase Inhibitors: 26301

Experts

1.	Mikhailidis, Dimitri P: 130 articles (07/2022 - 07/2002)
2.	Kastelein, John J P: 122 articles (01/2021 - 07/2002)
3.	Ballantyne, Christie M: 112 articles (11/2022 - 01/2002)
4.	Banach, Maciej: 104 articles (05/2022 - 12/2005)
5.	Rosenson, Robert S: 85 articles (12/2022 - 01/2002)
6.	Cannon, Christopher P: 85 articles (01/2022 - 04/2004)
7.	Sahebkar, Amirhossein: 84 articles (09/2022 - 08/2013)
8.	Toth, Peter P: 80 articles (01/2021 - 09/2004)
9.	Athyros, Vasilios G: 79 articles (01/2022 - 02/2002)
10.	Bhatt, Deepak L: 76 articles (10/2022 - 02/2002)

Related Diseases

1.	Cardiovascular Diseases (Cardiovascular Disease) 06/01/2020 - "Although statins are highly effective for reducing cardiovascular disease events, prior studies demonstrate their significant underuse in the US population, including among those with known atherosclerotic disease. " 01/01/2022 - "Given the potential improvement in accuracy in predicting cardiovascular disease when reduction in levels of non-HDL-C is used as the primary target, these findings provide guidance on which statin types and intensities are most effective by reducing non-HDL-C in patients with diabetes. " 01/01/2021 - "The comparative analysis of the effect of several doses of statins against different intensities of physical exercise on arterial stiffness (a measure of cardiovascular risk) could shed light for clinicians on which method is most effective in preventing cardiovascular disease (CVD) and be used to inform shared decision-making between doctors and patients. " 05/01/2012 - "The use of statins has scaled up to become one of the most prescribed medicines in the world and have been very useful in the manegement of cardiovascular diseases and related mortality. " 11/10/2009 - "Factors with the most influence on the results included risk of cardiac events/death after HL, efficacy of statins in reducing cardiac events/death, and costs of statins. "
2.	Stroke (Strokes) 09/01/2012 - "Although most of these studies were designed to evaluate cerebrovascular accidents (CVA) only as secondary endpoints, the data show a significant reduction in strokes associated with statin use. " 07/01/2010 - "The rate of statins usage is extremely low in stroke patients followed up in a general clinic, but it can been improved greatly in a stroke clinic. " 01/01/2008 - "Despite the fact that our understanding of the benefits of statins in stroke prevention is still evolving, we find marked room for improvement in stroke risk factor management. " 12/01/2005 - "Though effective in prevention of major coronary events after a first stroke, statins have not yet been proven effective in prevention of recurrent stroke." 03/01/2000 - "When trials that used different interventions were separately examined, a significant reduction in stroke occurrence was observed only for those using statins as active treatment (risk reduction 23%; 95% CI 13-33%). "
3.	Hypercholesterolemia 01/01/2021 - "Statins are first-line treatment for hypercholesterolemia and have been proven to reduce major vascular events in adults with and without underlying ASCVD. " 10/01/2018 - "Statin drugs have been used for more than two decades to treat hypercholesterolemia and as cardio-preventive drugs, resulting in a marked decrease in cardiovascular morbidity and mortality worldwide. " 06/01/2016 - "Widespread use of statins has improved hypercholesterolemia management, yet a significant proportion of patients remain at risk for cardiovascular (CV) events. " 01/01/2023 - "The 3 intricate issues requiring attention are (1) the impact of hypercholesterolemia on mortality and major adverse cardiovascular events in subjects >80 years, (2) the efficacy of statins to prevent cardiovascular events at this age, and (3) the safety and tolerance of statins in this population. " 10/01/1992 - "A look back indicates that HMG-CoA reductase inhibitors, as a class, appear to be safe and effective for long term use and constitute a major drug addition for the control of hypercholesterolemia. "
4.	Dyslipidemias (Dyslipidemia) 04/01/2015 - "Statins have been shown to be very effective and safe in numerous randomized clinical trials, and became the implacable first-line treatment against atherogenic dyslipidemia. " 09/01/2009 - "Statins have been extensively studied in a large variety of patient populations and have proven efficacy in the treatment of dyslipidemia, and in reducing CV mortality. " 03/01/2023 - "Those with full statin use were significantly more likely to be in the top tertile of WMH progression (adjusted odds ratio: 2.30, 95% confidence interval: 1.11-4.77, P =0.025), despite improvement in dyslipidemia. " 01/01/2018 - "Statins were also found to be beneficial in treating dyslipidemia and improving liver function. " 05/01/2020 - "Dietary changes and pharmacological management of dyslipidemias should be tailored to the type of dyslipidemia, with statins constituting the mainstay of treatment. "
5.	Neoplasms (Cancer) 03/01/2019 - "Statins were most potent against GBM, GIC, and other cancer cells with high TGF-β activity, and exogenous TGF-β further sensitized mesenchymal GICs to statins. " 06/20/2017 - "In a meta-analysis of 7 studies involving 5,449 patients with endocrine-related gynecologic cancers, statin use was linked to improved overall survival (HR, 0.71; 95% confidence interval [CI], 0.63 to 0.80) without significant heterogeneity (I2 = 33.3%). " 01/01/2023 - "Using a Cox proportional hazards model, significant reduction in cancer risk was observed in statin users compared with that in drug nonusers [adjusted HR = 0.84; 95% confidence interval (CI), 0.72-0.97; adjusted for patient background factors]. " 09/01/2022 - "However, statin use was associated with a significant reduction in overall and cancer-related mortality. " 01/22/2022 - "The results showed that statin use was associated with a significant reduction in the risks of all-cause mortality (hazard ratio (HR) = 0.73, 95% confidence interval (CI) = 0.64-0.84, p < 0.0001) and cancer-specific mortality (HR = 0.61, 95% CI = 0.49-0.77, p < 0.0001) in PCa patients receiving ADT. "

Related Drugs and Biologics

1.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
2.	Lipids
3.	Cholesterol
4.	oxidized low density lipoprotein
5.	LDL Cholesterol
6.	Ezetimibe (Zetia)
7.	Coenzyme A (CoA)
8.	Atorvastatin (Lipitor)
9.	Aspirin (Acetylsalicylic Acid)
10.	Oxidoreductases (Dehydrogenase)

Related Therapies and Procedures

1.	Therapeutics
2.	Secondary Prevention
3.	Drug Therapy (Chemotherapy)
4.	Percutaneous Coronary Intervention
5.	Radiotherapy